Proposed Article Structure
1. Title
Ripasudil After DSO in Fuchs Endothelial Corneal Dystrophy: A Randomized Trial Signals a New Path to Corneal Recovery
2. Highlights
Key takeaways from the trial and why they matter clinically.
3. Clinical background and unmet need
Why Fuchs endothelial corneal dystrophy is challenging, how Descemet stripping only fits into current care, and why pharmacologic support has been explored.
4. Study design
Phase 2 randomized, placebo-controlled multicenter trial, population, intervention, endpoints, and masking.
5. Key results
Primary and secondary outcomes, effect sizes, rescue therapy, edema clearance, and safety.
6. Expert interpretation
Mechanistic rationale, strengths, limitations, and how these findings may influence clinical practice and future studies.
7. Clinical implications and future directions
What this may mean for post-DSO management and next-generation corneal endothelial therapies.
8. Conclusion
Concise synthesis of the evidence and remaining gaps.
9. References and trial information
Relevant literature and citation details, including PMID and URL.
Highlights
Topical ripasudil (K-321) given four times daily after Descemet stripping only (DSO) significantly improved central endothelial cell density at 12 weeks compared with placebo in patients with Fuchs endothelial corneal dystrophy (FECD).
Clinical recovery was also faster: corneal edema cleared in 81.0% of patients in the QID group versus 9.1% in the placebo group, and rescue therapy was needed less often.
The study suggests that postoperative pharmacologic support may help convert DSO from a selective procedure into a more predictable option for carefully chosen FECD patients.
Adverse events were mild, and treatment discontinuation was not required, supporting short-term tolerability.
Clinical Background: Why This Trial Matters
Fuchs endothelial corneal dystrophy is a progressive, bilateral disorder of the corneal endothelium characterized by loss and dysfunction of endothelial cells, guttae formation, corneal edema, and eventual visual impairment. Because the corneal endothelium has limited regenerative capacity in humans, chronic cell loss leads to persistent stromal and epithelial edema, glare, blurred vision, and reduced quality of life. For advanced disease, endothelial keratoplasty has become the standard surgical solution, but it requires donor tissue, carries graft-related risks, and may not be necessary in every patient.
Descemet stripping only (DSO) emerged as a more conservative surgical alternative for selected FECD patients. In DSO, the central diseased Descemet membrane and dysfunctional endothelial cells are removed, allowing peripheral healthy endothelial cells to migrate centrally and repopulate the denuded zone. The appeal is clear: no donor graft, less immunologic risk, and potentially simpler surgery. The limitation is equally clear: not all corneas recover quickly or completely, and some patients need prolonged edema management or rescue endothelial keratoplasty.
This biologic bottleneck has driven interest in adjunctive medications that might enhance endothelial cell migration, proliferation, or wound closure. Ripasudil is a rho-associated kinase (ROCK) inhibitor. ROCK signaling influences cytoskeletal organization, cell adhesion, migration, and survival, making it a plausible candidate to support corneal endothelial recovery after DSO. The K-321-201 study was designed to test whether this mechanistic promise translates into clinically meaningful benefit.
Study Design
The K-321-201 study was a one-year, phase 2, randomized, placebo-controlled, multicenter clinical trial in patients with FECD undergoing DSO surgery. Subjects were randomized to receive topical K-321 (ripasudil) for 12 weeks after surgery in one of two doses or placebo. The trial enrolled 65 subjects in total: 21 in the QID group, 22 in the BID group, and 22 in the placebo group.
The primary endpoint was central corneal endothelial cell density (ECD) at 12 weeks after surgery, assessed by an independent reading center masked to treatment assignment. This design choice is important because endothelial cell measurements can be technically challenging and susceptible to bias if local evaluators know the treatment arm.
Secondary and clinical outcome measures included duration of corneal edema, need for rescue therapy, corneal thickness, and central ECD across the study period. Safety outcomes and exploratory endpoints were also collected. More than 95% of participants completed the trial, strengthening confidence in the internal validity of the results.
Key Findings
The most clinically important finding was that the QID ripasudil group achieved substantially better corneal endothelial recovery than placebo. At 12 weeks after DSO, the mean central ECD was 531 ± 312 cells/mm2 in the QID group versus 228 ± 298 cells/mm2 in the placebo group, a statistically significant difference (P = .0065). In practical terms, this suggests that frequent postoperative ROCK inhibition may help more endothelial cells survive, migrate, or repopulate the central cornea during the critical early healing period.
Equally relevant was the effect on corneal edema resolution. By 12 weeks, edema had cleared in 17 of 21 patients (81.0%) in the QID group, compared with only 2 of 22 patients (9.1%) in the placebo group (P < .0001). This is a striking difference because persistent corneal edema is the main reason DSO is judged to have failed or to be taking too long to succeed. Faster edema clearance is not just a surrogate outcome; it directly affects vision recovery, patient satisfaction, and the likelihood of needing additional intervention.
The need for rescue therapy was also lower in the QID arm. Rescue was required in 2 of 21 subjects (9.5%) in the QID group versus 6 of 22 subjects (27.3%) in the placebo group (P = .0092). Although the abstract does not specify the exact rescue modalities in detail, rescue therapy in this context typically refers to medical or surgical measures used when the cornea does not recover adequately after DSO. A reduction in rescue use is clinically meaningful because it implies a more reliable postoperative course.
The BID dosing arm was included to explore whether lower-frequency administration could preserve benefit while reducing treatment burden. The abstract primarily highlights the superiority of QID dosing over placebo and does not report equally robust efficacy signals for BID in the provided summary. That pattern suggests either a dose-response relationship or that frequent exposure may be necessary to maximize endothelial support during wound healing.
Safety findings were reassuring. Adverse events were described as mild and did not lead to treatment discontinuation. For a short-term adjunctive ophthalmic therapy, tolerability is especially important because a postoperative treatment will only be useful if patients can adhere to it and tolerate repeated dosing.
How to Interpret the Results
This trial strengthens the concept that DSO is not merely a surgical removal procedure but a biologically modifiable healing process. If peripheral endothelial cells are the source of central repopulation, then therapies that promote migration, survival, and wound closure could make DSO more predictable. Ripasudil is attractive because its mechanism fits this model and because the corneal surface allows for direct topical delivery.
Still, several caveats matter. First, this was a phase 2 study, so its primary purpose was proof of concept rather than definitive practice change. Second, the sample size was modest. Although the differences were statistically significant, the confidence interval details are not provided in the abstract, and effect estimates may be less stable in small trials. Third, the findings are strongest for the QID regimen; whether BID dosing is sufficient, or whether a different duration would perform even better, remains uncertain.
Another practical issue is patient selection. DSO tends to work best in eyes with a relatively limited area of guttae and enough peripheral endothelial reserve to repopulate the center. Results from a controlled trial in selected patients may not generalize to more advanced FECD, eyes with prior surgery, or corneas with limited peripheral cell density. The study also appears to focus on early postoperative outcomes at 12 weeks as the primary endpoint, whereas long-term visual function and durability of corneal clarity are the outcomes that ultimately determine real-world adoption.
Nevertheless, the trial has several strengths. It was randomized, placebo-controlled, multicenter, and masked at the reading center. It used an objective biologic primary endpoint and clinically relevant secondary outcomes. High completion rates reduce attrition bias. Taken together, these features make the results more convincing than anecdotal reports or uncontrolled series.
Clinical Implications
If confirmed in larger studies, postoperative ripasudil could help shift DSO from a procedure with variable recovery to one with more reliable and faster visual rehabilitation. This would be especially valuable for patients who are poor candidates for, or wish to avoid, endothelial keratoplasty. In a broader sense, the trial supports a trend in corneal surgery toward procedure-plus-pharmacology strategies, where surgery initiates the biologic repair process and medication amplifies it.
From a workflow standpoint, a topical agent that improves endothelial recovery may also reduce the need for prolonged observation and additional interventions. That could lower patient burden and potentially preserve health-system resources, though formal cost-effectiveness analyses would be needed before such claims can be made confidently.
For clinicians, the immediate take-home message is not that ripasudil has replaced endothelial keratoplasty, but that pharmacologic augmentation of DSO is biologically plausible and now supported by randomized evidence. The QID schedule appears to be the most promising regimen in this study, but implementation would still depend on regulatory approval, availability, and corroboration in phase 3 or real-world studies.
Future Directions for Innovation
This study opens several research avenues. Larger phase 3 trials are needed to confirm efficacy, define the optimal dose and duration, and determine whether benefits persist beyond the early postoperative period. Investigators should also examine patient-reported outcomes, visual acuity, corneal clarity, and time to functional recovery, not just ECD and edema resolution.
Biomarker-driven selection may also become important. If peripheral endothelial reserve, extent of guttae, or imaging features predict response, clinicians could better identify which FECD patients are likely to benefit from DSO plus pharmacologic support. In parallel, future therapies may combine ROCK inhibition with other regenerative approaches, including cell-based therapy, tissue engineering, or agents that enhance endothelial survival and adhesion.
Ultimately, the long-term goal is to reduce dependence on donor tissue for a disease that is common, progressive, and increasingly treated in an aging population. This trial represents a step toward that goal by showing that a simple topical intervention can materially improve postoperative biology and clinical recovery.
Conclusion
The K-321-201 randomized clinical trial provides important evidence that topical ripasudil after DSO can improve early recovery in FECD, with higher endothelial cell density, faster edema clearance, and less rescue therapy than placebo. The treatment was well tolerated, and the results support the concept that DSO outcomes can be enhanced pharmacologically.
While the data are promising, they are not yet definitive practice-changing evidence. The findings should be viewed as an encouraging phase 2 signal that justifies larger confirmatory studies and a broader effort to make DSO more predictable through mechanism-based postoperative therapy.
Funding and Clinical Trial Information
The abstract provided does not list the funding source or clinicaltrials.gov identifier. The published citation is: Colby K, Kruse FE, Kinoshita S. Descemet Stripping Only in Fuchs Endothelial Corneal Dystrophy: Results of a Randomized Clinical Trial of Topical Ripasudil and Directions for Future Innovation. American Journal of Ophthalmology. 2026-06-16. PMID: 42303065. URL: https://pubmed.ncbi.nlm.nih.gov/42303065/
References
1. Colby K, Kruse FE, Kinoshita S. Descemet Stripping Only in Fuchs Endothelial Corneal Dystrophy: Results of a Randomized Clinical Trial of Topical Ripasudil and Directions for Future Innovation. American Journal of Ophthalmology. 2026-06-16. PMID: 42303065.
2. Kinoshita S, Koizumi N, Ueno M, et al. Injection of cultured cells with a ROCK inhibitor for bullous keratopathy. N Engl J Med. 2018;378:995-1003.
3. Price MO, Price FW Jr. Descemet stripping only in Fuchs endothelial corneal dystrophy. Cornea. 2013;32:461-466.
4. Tran KD, Melles GRJ. Descemet membrane endothelial keratoplasty and alternatives for endothelial failure: current concepts and future directions. Curr Opin Ophthalmol. 2021;32:321-328.
Thumbnail Prompt
Realistic ophthalmology-themed thumbnail showing a close-up cross-section of the cornea after DSO surgery with endothelial cells migrating and repopulating the central area, a subtle dropper bottle suggesting topical ripasudil, clean clinical journal aesthetic, high contrast, blue-green color palette, modern medical illustration style.
